Movement Disorder Virtual University WE MOVE
Research News
E-MOVE - Research News Service Subscribe to E-MOVE

Search Research News
Any Words All Words Exact Phrase

E-MOVE Archives 2002

ID date title
405 1/1/2002 IVIg for Stiff-Person Syndrome
406 1/2/2002 Transdermal PD Treatments
408 1/11/2002 AAN Practice Parameter for Early PD
407 1/11/2002 Synuclein Accumulation is Enhanced by Amyloid, Pesticides
409 1/17/2002 New WE MOVE Online Continuing Medical Education
410 1/18/2002 Treatment of Depression and Erectile Dysfunction in PD
411 1/25/2002 Complications from Gamma Knife PD Surgery
412 2/5/2002 Factors Affecting PD Quality of Life
413 2/9/2002 Announcement: Movement Disorders Review Courses in 2002
414 2/11/2002 In Utero Exposure to Bacterial Toxin Reduces Dopaminergic Neurons in Rats
416 2/15/2002 Cannabinoids Reduce Dyskinesias, but not Dystonia
415 2/15/2002 Supplement on Rett Syndrome (Journal Contents)
417 2/22/2002 Environmental Factors Trigger Aggregation of Alpha-Synuclein
418 3/5/2002 Methylphenidate and Clonidine for ADHD with Comorbid Tics
419 3/6/2002 RLS: Susceptibility Locus, Opioid Treatment
421 3/8/2002 Histone Deacetylase Inhibitors Reduce Polyglutamine Neurodegeneration
420 3/8/2002 ITB for Generalized Dystonia: 86 Cases
422 3/11/2002 Announcement: World Congress & Exposition on Disabilities
423 3/15/2002 Common Genes Influence Age of Onset in PD and AD
425 3/18/2002 Announcement: E-MOVE at the AAN
424 3/18/2002 A Message From WE MOVE
426 4/8/2002 Pramipexole Slows Nigral Cell Loss Compared to Levodopa
427 4/8/2002 WE MOVE at the AAN
429 4/18/2002 Pallidal Surgery for Generalized Dystonia (AAN 2002)
430 4/18/2002 Metoclopramide for Tourette Syndrome (AAN 2002)
428 4/18/2002 Brain Activation is Changed in PD Patients Who Hallucinate (AAN 2002)
431 4/19/2002 Nurr1 Gene Mutations in Familial PD (AAN 2002)
432 4/19/2002 ET: Hearing Loss, DBS (AAN 2002)
433 4/19/2002 Testosterone Deficiency in Men with PD (AAN 2002)
434 4/21/2002 Ropinirole Slows Loss of Dopaminergic Marker (AAN 2002)
435 4/23/2002 Proteasome Inhibition Causes Nigral Cell Death (AAN 2002)
436 4/23/2002 Putaminal GDNF Administration, Retinal Epithelial Cells Improve PD Symptoms (AAN 2002)
437 4/23/2002 Anti-BTX-A Antibodies in Spasticity Patients (AAN 2002)
438 4/24/2002 Treatment of Psychosis in PD Patients (AAN 2002)
439 4/24/2002 Adenosine Antagonist Reduces Off Time (AAN 2002)
440 4/25/2002 PD Caregiver Strain Is Not Primarily Due To Motor Symptoms (AAN 2002)
441 4/25/2002 RLS: Increased Hypocretin, Familial Aggregation (AAN 2002)
442 4/25/2002 HD: Mode of Onset and Progression; Creatine Trial (AAN 2002)
443 4/26/2002 Essential Tremor: Treatment, Misdiagnosis (AAN 2002)
444 5/2/2002 Announcement: AAN 2002 Reports Archived On WE MOVE Site
445 5/6/2002 Announcement: AAN 2002 Reports Archived On WE MOVE Site
446 5/6/2002 New Warning for Clozapine
447 5/19/2002 DBS for Movement Disorders (Journal Supplement)
448 5/20/2002 Botox-Dysport Ratio of Unit Potency is Less Than 1:3 in Cervical Dystonia
449 5/21/2002 Announcement: AAN 2002 Reports Archived On WE MOVE Site (correction)
450 5/21/2002 HFS: Long-Term Results from BTX, Surgery
451 5/24/2002 DATATOP Follow-Up: Deprenyl Decreases Freezing and On-Off Fluctuations, Increases Dyskinesias
452 5/30/2002 News from WE MOVE on E-Mail Viruses
453 6/4/2002 Announcement: WE MOVE at Toxins 2002
455 6/15/2002 Ultrasound Guidance for BTX Injection (Toxins 2002)
456 6/15/2002 Neurotrophic Effects of Clostridium Toxin C3 (Toxins 2002)
457 6/15/2002 Treatment of Writer's Cramp (Toxins2002)
454 6/15/2002 Double-blind Trial of BTX-A for Drooling (Toxins 2002)
458 6/18/2002 Double-blind Trial of BTX-A for Drooling (Toxins 2002)
459 6/24/2002 Double-blind Trial of BTX-A for Drooling (Toxins 2002)
460 6/27/2002 BTX-B for Blepharospasm (Toxins 2002)
461 6/27/2002 BTX Effects on Peripheral Nociception (Toxins 2002)
462 6/27/2002 Treatment of Bladder Spasticity (Toxins2002)
463 6/28/2002 Low-Dose BTX-B for Hyperhidrosis (Toxins2002)
464 6/28/2002 Reduced Immunogenicity of Current BOTOX (Toxins2002)
465 6/29/2002 BTX-B for Piriformis Syndrome (Toxins2002)
466 7/1/2002 Toxins 2002 Collected Reports Available
467 7/6/2002 Functional Dopamine Neurons From Mouse Embryonic Stem Cells
468 7/8/2002 Persistence and Emergence of Behavioral Disorders Following Deep Brain Stimulation
469 7/9/2002 Budipine As Adjunct Therapy in PD
470 7/11/2002 Tardive Dyskinesia: Genetics, Remission
471 7/12/2002 Intrathecal Baclofen: Abrupt Withdrawal, Cost/Benefit Analysis
472 7/13/2002 Post-Rhizotomy Strength
473 7/14/2002 Spasticity Treatment: Cannabis, Modafinil
474 7/19/2002 Treatments of Polyglutamine Diseases in Model Systems
475 7/25/2002 Transcription Disruption Causes Neurodegeneration in HD Models
476 7/26/2002 Post-Graft Off Dyskinesias Are Common in PD Transplant Patients
477 7/29/2002 Comprehensive Botulinum Toxin Book Published
478 8/16/2002 Evidence-Based Review of Parkinson's Disease Management (Journal Contents)
479 8/19/2002 Lisuride Infusion Reduces Motor Complications in PD
480 8/31/2002 Osteoporosis Treatment, HRT Plus Selegiline
481 9/3/2002 Lack of Treatment Effect of Hyperbaric Oxygen in CP
482 9/3/2002 Smoking and Coffee Drinking in Parkinson's Disease
483 9/6/2002 Announcement: WE MOVE at AACP&DM Annual Meeting
484 9/6/2002 Topiramate for Essential Tremor
485 9/8/2002 Mutant Huntingtin Causes Early Mitochondrial Calcium Defects
486 9/8/2002 Announcement: Tics and Tourette's Syndrome Slide Kit Available
487 9/9/2002 Announcement: Online CME Activity from WE MOVE
488 9/14/2002 BTX, Casting, and PT for Idiopathic Toe Walking (AACPDM Report)
489 9/14/2002 Comparison of BTX and Casting for Equinus (AACPDM Report)
490 9/16/2002 Selective Dorsal Rhizotomy Outcomes (AACPDM Report)
491 9/16/2002 Scoliosis Progression After Intrathecal Baclofen Therapy (AACPDM Report)
492 9/20/2002 CP: Assessment, Pain Relief (AACPDM Report)
493 9/20/2002 Effects of Intrathecal Baclofen on Care, Comfort, and Gait (AACPDM Report)
494 9/26/2002 Announcement: The Child Neurology Society's Annual Meeting October 9-12 in Washington, DC
495 9/30/2002 Announcement: The Child Neurology Society's Annual Meeting October 9-12 in Washington, DC
496 9/30/2002 Announcement: The Child Neurology Society's Annual Meeting October 9-12 in Washington, DC
497 10/1/2002 Announcement: The Child Neurology Society's Annual Meeting October 9-12 in Washington, DC
498 10/2/2002 Announcement: AACPDM 2002 Reports Archived On the WE MOVE Site
499 10/7/2002 Announcement: WE MOVE at the American Neurological Association Meeting
500 10/8/2002 Actin Aggregation in a New Form of Juvenile-Onset Dystonia
501 10/8/2002 MSA: Progression, Hypoxia Response
502 10/14/2002 GDNF Restores Behavioral and Cell Function in PD Models
503 10/14/2002 Coenzyme Q10 for Early Parkinson's Disease
504 10/28/2002 Mitochondrial Impairment in PD Pathogenesis
505 10/31/2002 Long-Term Hardware Complications of Deep Brain Stimulation
506 10/31/2002 Neurotoxicology of Parkinson’s Disease (Journal Contents)
507 11/1/2002 “Ecstasy” Causes Severe Dopaminergic Neurotoxicity in Primates
508 11/4/2002 Announcement: WE MOVE at the Movement Disorders Congress
509 11/5/2002 Announcement--New Dystonia Scales Available from WE MOVE
510 11/15/2002 No Symptomatic Benefit in Second Fetal Transplant Double-Blind Trial (MovDis Congress 2002)
511 11/17/2002 Dystonia Long-Term Follow-up (Movement Disorder Congress 2002)
512 11/18/2002 Cabergoline for RLS (Movement Disorder Congress 2002)
514 11/18/2002 WE MOVE at the AAPM&R
513 11/18/2002 Dystonia Research Funds Available from NIH
517 11/19/2002 Tardive Dyskinesia: Etiology, Treatment (Movement Disorders Congress 2002)
515 11/19/2002 Essential Tremor Treatment (Movement Disorder Congress 2002)
516 11/19/2002 ELLDOPA: Early Levodopa Does Not Hasten PD Decline (Movement Disorders Congress 2002)
518 11/20/2002 Phenomenology and Treatment of Tics (Movement Disorder Congress 2002)
519 11/20/2002 Gabapentin for RLS (Movement Disorder Congress 2002)
524 11/24/2002 Long-term DBS Follow-up (Movement Disorders Congress 2002)
522 11/24/2002 Characteristics and Treatment of Motor Complications in PD (Movement Disorders Congress 2002)
520 11/24/2002 Announcement: DBS CME Course
521 11/24/2002 BTX-B Long-term Follow-up (Movement Disorders Congress 2002)
523 11/24/2002 D2 Agonist Sumanirole for PD (Movement Disorders Congress 2002)
525 11/25/2002 Loss of Benefit from BTX Treatment in Cervical Dystonia (Movement Disorders Congress 2002)
526 11/25/2002 Nocturnal Pain, Melatonin in PD (Movement Disorders Congress 2002)
527 11/27/2002 NSAID Use Correlates with Reduced PD Risk (Movement Disorders Congress 2002)
528 11/27/2002 Pallidal DBS for Dystonia (Movement Disorders Congress 2002)
529 11/27/2002 Randomized Blinded PD Surgery Comparison (Movement Disorders Congress 2002)
531 11/29/2002 Bilateral Subthalamotomy for PD (Movement Disorders Congress 2002)
530 11/29/2002 Riluzole Is Ineffective in PD and MSA (Movement Disorders Congress 2002)
532 11/29/2002 Transcranial Ultrasound for Differential Diagnosis of Parkinsonism (Movement Disorders Congress 2002
533 12/2/2002 Apomorphine: Long-Term Results, Nasal Delivery (Movement Disorders Congress 2002)
534 12/6/2002 Available from WE MOVE: Toxins 2002 Meeting Report
535 12/6/2002 Treatment of Spasticity with 4-Aminopyridine (AAPMR 2002)
539 12/11/2002 A Message from WE MOVE
537 12/11/2002 Pergolide Monotherapy Without Domperidone (Movement Disorders Congress 2002)
536 12/11/2002 BTX for Sialorrhea (Movement Disorders Congress 2002)
540 12/13/2002 Rotigotine Patch for RLS (Movement Disorders Congress 2002)
542 12/27/2002 Pediatric Toxin Injections: Adverse Events (AAPMR 2002)
543 12/27/2002 Tizanidine for Intention Myoclonus, Stuttering (AAPMR 2002)
541 12/27/2002 BTX-B in Pediatric Patients (AAPMR 2002)

 
All contents copyright © WE MOVE 2013. This page last modified 3/5/2008.